THC (Delta-9 Tetrahydrocannabinol)

<p>Delta-9 tetrahydrocannabinol, universally known as THC, is the principal psychoactive constituent of cannabis and the molecule responsible for the plant's characteristic intoxicating effects. Discovered and isolated by Israeli chemist Raphael Mechoulam in 1964, THC remains the most studied, most sought-after, and most legally contentious compound in the cannabis plant. Its presence defines the boundary between hemp and marijuana in regulatory frameworks, and its concentration drives product potency claims across dispensary shelves.</p><h2>Chemical Structure and Biosynthesis</h2><p>THC is a terpenophenolic compound with the molecular formula C₂₁H₃₀O₂. It exists as one of several dozen cannabinoids produced in cannabis trichomes, where it originates not as THC itself but as <a href="/glossary/thca">THCA</a> (tetrahydrocannabinolic acid). THCA is non-intoxicating and abundant in raw cannabis flower. Only through decarboxylation, a process triggered by heat during smoking, vaping, or cooking, does THCA shed its carboxyl group and convert into active THC. This conversion is why raw cannabis consumption produces negligible psychoactive effects while combustion or controlled heating unlocks THC's full pharmacological profile.</p><p>The biosynthetic pathway also produces <a href="/glossary/cbd">CBD</a>, <a href="/glossary/cbg">CBG</a>, <a href="/glossary/cbc">CBC</a>, <a href="/glossary/thcv">THCV</a>, and <a href="/glossary/cbn">CBN</a>, each with distinct receptor affinities and effects. CBG serves as the precursor to both THC and CBD, while CBN forms as THC degrades through oxidation and aging.</p><h2>Mechanism of Action</h2><p>THC exerts its effects primarily through agonism of cannabinoid receptor type 1 (CB1), a G-protein coupled receptor densely concentrated in the central nervous system, particularly in the hippocampus, cerebral cortex, cerebellum, and basal ganglia. This receptor distribution explains THC's influence over memory, cognition, motor coordination, and reward processing. When THC binds to CB1 receptors, it modulates neurotransmitter release, inhibiting the release of GABA and glutamate and indirectly increasing dopamine signaling in the mesolimbic pathway, the brain's reward circuitry.</p><p>THC also interacts, though with lower affinity, with CB2 receptors found predominantly in peripheral tissues and immune cells. This interaction contributes to anti-inflammatory and immunomodulatory effects but is not responsible for intoxication. The endocannabinoid system, comprising these receptors and endogenous ligands like anandamide and 2-AG, evolved long before cannabis consumption and regulates homeostatic functions including appetite, pain sensation, mood, and memory.</p><h2>Psychoactive Effects and Intoxication</h2><p>THC's subjective effects vary widely based on dose, route of administration, individual tolerance, and genetic factors. Commonly reported acute effects include euphoria, relaxation, altered sensory perception, time distortion, increased sociability, and heightened appreciation of music or food. Cognitive changes include short-term memory impairment, reduced attention span, and impaired executive function. Motor skills decline, contributing to increased accident risk, particularly in driving scenarios.</p><p>The dose-response curve for THC is steep. Low doses may produce mild relaxation and mood elevation, while moderate doses induce clear intoxication with perceptual changes. High doses, particularly in naive users or through edible overconsumption, can trigger acute anxiety, paranoia, tachycardia, and in rare cases, cannabis-induced psychosis characterized by hallucinations and disorientation. These adverse reactions are more common with high-potency concentrates and edibles, where delayed onset leads users to consume more before effects manifest.</p><p>Terpenes co-occurring in cannabis, including <a href="/glossary/myrcene">myrcene</a>, <a href="/glossary/limonene">limonene</a>, and <a href="/glossary/linalool">linalool</a>, may modulate THC's effects through the entourage effect, though clinical evidence remains limited. Myrcene is theorized to enhance sedation, while limonene may provide mood elevation.</p><h2>Pharmacokinetics: Inhalation, Oral, and Sublingual Routes</h2><p>Route of administration profoundly affects THC's onset, peak, and duration. Inhalation via smoking or vaporization delivers THC rapidly across the pulmonary epithelium into systemic circulation, producing effects within minutes and peak plasma concentrations around 10 minutes post-inhalation. Bioavailability ranges from 10% to 35%, with effects lasting two to four hours. This rapid onset allows users to titrate dosage incrementally.</p><p>Oral ingestion presents a starkly different profile. THC consumed in edibles undergoes first-pass hepatic metabolism, where cytochrome P450 enzymes convert delta-9 THC into 11-hydroxy-THC, a more potent and longer-lasting metabolite with greater blood-brain barrier penetration. Onset delays 30 minutes to two hours, peak effects occur around three hours, and duration extends six to eight hours or longer. Bioavailability drops to 4% to 12% due to hepatic metabolism and gastrointestinal degradation. This delayed, prolonged profile increases overdose risk among inexperienced users.</p><p>Sublingual tinctures and oromucosal sprays bypass first-pass metabolism partially, offering onset within 15 to 45 minutes and bioavailability intermediate between inhalation and ingestion. Transdermal patches provide sustained release but limited CNS penetration, minimizing intoxication while delivering systemic effects.</p><h2>Medical and Therapeutic Applications</h2><p>THC holds established therapeutic utility in several clinical contexts. The FDA has approved synthetic THC formulations, dronabinol (Marinol) and nabilone (Cesamet), for chemotherapy-induced nausea and vomiting and AIDS-related anorexia. These applications use THC's potent antiemetic and appetite-stimulating properties, mediated through CB1 activation in brainstem emetic centers and hypothalamic appetite circuits.</p><p>Pain management represents another major therapeutic domain. THC demonstrates analgesic efficacy in neuropathic pain, cancer pain, and chronic pain conditions, though evidence quality varies and effect sizes are often modest. Its mechanism involves both central analgesic pathways and peripheral anti-inflammatory action via CB2 receptors. Muscle spasticity in multiple sclerosis responds to THC, as evidenced by approval of nabiximols (Sativex), a 1:1 THC:CBD oromucosal spray, in multiple countries outside the United States.</p><p>Emerging research explores THC's potential in PTSD, where it may facilitate fear extinction and reduce nightmares, and in neurodegenerative diseases, where its neuroprotective and anti-inflammatory properties show preclinical promise. However, cognitive side effects and abuse liability complicate clinical deployment. The presence of <a href="/glossary/cbd">CBD</a> in full-spectrum formulations may mitigate anxiety and cognitive impairment associated with THC monotherapy.</p><h2>Drug Testing and Detection Windows</h2><p>THC and its metabolites, particularly 11-nor-9-carboxy-THC (THC-COOH), are lipophilic and accumulate in adipose tissue, resulting in prolonged detection windows that exceed intoxication duration by days or weeks. Urinalysis, the most common workplace screening method, detects THC-COOH rather than active THC. Occasional users may test positive for three to seven days post-use, while daily users can test positive for 30 days or longer due to cannabinoid accumulation and slow release from fat stores.</p><p>Blood tests detect active THC and correlate more closely with recent use and impairment, making them preferable for per se driving laws. THC is detectable in blood for hours to one day in occasional users and longer in chronic users. Saliva testing offers a non-invasive alternative with detection windows of 24 to 72 hours, suitable for roadside impairment screening. Hair testing can detect historical use for up to 90 days but cannot distinguish recent from past use and is subject to environmental contamination.</p><h2>Legal Status and Schedule III Reclassification</h2><p>THC's legal status has shifted dramatically. Federally, cannabis containing more than 0.3% THC by dry weight remains controlled, but the DEA's 2024 rescheduling moved marijuana from Schedule I to Schedule III under the Controlled Substances Act. This reclassification acknowledges accepted medical use and lower abuse potential relative to Schedule I and II substances, aligning federal policy closer to scientific consensus and state-level medical cannabis programs. Schedule III status permits additional research and changes tax treatment for cannabis businesses under IRS Code 280E, but does not legalize recreational possession or interstate commerce.</p><p>State laws vary widely. As of 2024, 24 states and Washington D.C. have legalized adult-use cannabis, while 38 states permit medical use. Delta-8 THC, a hemp-derived isomer with similar but reportedly milder psychoactive effects, occupies a legal gray zone. Synthesized from <a href="/glossary/cbd">CBD</a> extracted from hemp, delta-8 products proliferated under the 2018 Farm Bill's hemp legalization, though several states have banned or regulated it due to safety and regulatory concerns.</p><h2>Potency Trends and Public Health Considerations</h2><p>Cannabis potency has increased markedly over the past three decades. Average THC concentration in seized flower rose from approximately 4% in the 1990s to 15% or higher in contemporary legal markets, with some strains exceeding 30%. Concentrates, including shatter, wax, and distillate, routinely contain 70% to 90% THC. This potency inflation raises concerns about dose-related harms, including acute psychiatric episodes, cannabinoid hyperemesis syndrome, and potential links to cannabis use disorder.</p><p>Cannabis use disorder, characterized by tolerance, withdrawal, and compulsive use despite negative consequences, affects approximately 9% of users, rising to 17% among adolescent-onset users. Withdrawal symptoms include irritability, sleep disturbance, appetite changes, and craving, typically emerging within 24 to 48 hours of cessation and persisting one to two weeks. While less severe than opioid or alcohol withdrawal, these symptoms are clinically significant and complicate cessation efforts.</p><h2>Interactions and Contraindications</h2><p>THC interacts with numerous medications through pharmacokinetic and pharmacodynamic pathways. It inhibits and induces cytochrome P450 enzymes, particularly CYP3A4 and CYP2C9, potentially altering concentrations of co-administered drugs including warfarin, clobazam, and certain immunosuppressants. Additive CNS depression occurs with alcohol, benzodiazepines, and opioids, increasing sedation and respiratory depression risk.</p><p>Contraindications include unstable cardiovascular disease, given THC's cardiovascular effects including tachycardia and orthostatic hypotension, and personal or family history of psychotic disorders, where THC may precipitate or exacerbate symptoms. Pregnancy and breastfeeding represent additional contraindications due to potential neurodevelopmental effects, though research remains limited and confounded by polysubstance use.</p><h2>THC in Context</h2><p>THC's dominance in cannabis discourse reflects its unique status as both therapeutic agent and intoxicant. Its effects cannot be separated from set, setting, dose, and individual biology. Understanding THC requires moving past binary legalization debates toward nuanced consideration of use patterns, product types, and harm reduction strategies. As legal markets mature and research restrictions ease under Schedule III, a clearer picture of THC's risks and benefits will emerge, informing evidence-based policy and clinical practice.</p>